A Systematic Review of the Effectiveness of Hydrogen Therapy in Hearing Loss Authors: CongZhong Wang, Mailudan Ainiwaer, Zheng Jiang, LongHao Wang Published: 2026 ABSTRACT Background:Hydrogen (H2) therapy demonstrates selective antioxidant and anti-inflammatory properties with potential therapeutic value for multiple forms of hearing loss, though consolidated evidence is still lacking.Methods:We conducted a systematic review following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, searching PubMed, MEDLINE, and DOAJ (until March 1, 2025) for studies on H2 treatment for noise-induced hearing loss (NIHL), drug-induced hearing loss (DIHL), radiotherapy-induced hearing loss (RIHL), and idiopathic sudden sensorineural hearing loss (ISSNHL). After screening by two reviewers, 11 studies involving human or animal subjects were included. Data were synthesized by hearing loss type, and the Systematic Review Centre for Laboratory Animal Experimentation tool assessed bias risk in animal studies.Results:In NIHL models, H2 administration reduced Auditory Brainstem Response threshold shifts and improved Distortion Product Otoacoustic Emissions recovery, while preserving cochlear morphology via reactive oxygen species (ROS) suppression. For DIHL, inhaled H2 protected hair cells and spiral ganglion neurons through ROS scavenging and apoptosis inhibition. Clinically, H2 inhalation improved hearing in RIHL patients post-radiotherapy. One randomized trial in ISSNHL showed H2 combined with standard therapy significantly enhanced hearing recovery.Conclusion:H2 exhibits protective effects in preclinical NIHL and DIHL models, and promising outcomes in clinical RIHL and ISSNHL, primarily via antioxidative and anti-inflammatory mechanisms. Further trials are required to establish optimal protocols and confirm efficacy. CongZhong Wang and Mailudan Ainiwaer are co-first authors. These authors contributed equally to this work. KEY MESSAGES (1)Hydrogen therapy effectively alleviates damage in animal models of noise-induced hearing loss and drug-induced hearing loss, preserving cochlear structures, and improving auditory function. Hydrogen therapy effectively alleviates damage in animal models of noise-induced hearing loss and drug-induced hearing loss, preserving cochlear structures, and improving auditory function. (2)The therapeutic effect stems from H2’s selective scavenging of harmful reactive oxygen species, thereby reducing oxidative stress and inflammation, which are key contributors to hearing loss. The therapeutic effect stems from H2’s selective scavenging of harmful reactive oxygen species, thereby reducing oxidative stress and inflammation, which are key contributors to hearing loss. (3)Preliminary human studies show H2 inhalation, when combined with standard therapy, significantly enhances hearing recovery in patients with radiotherapy-induced hearing loss and idiopathic sudden sensorineural hearing loss. Preliminary human studies show H2 inhalation, when combined with standard therapy, significantly enhances hearing recovery in patients with radiotherapy-induced hearing loss and idiopathic sudden sensorineural hearing loss. INTRODUCTION Hearing loss is a common sensory impairment that profoundly impacts the quality of life for a significant portion of the global population. Its causes are diverse, including genetic factors, aging, excessive noise exposure, infections, and ototoxic medications. For example, idiopathic sudden sensorineural hearing loss (ISSNHL) often presents suddenly, typically affecting one ear, with an incidence of 60.9 per 100,000 individuals in Japan.[1] The consequences of hearing loss extend beyond communication difficulties, contributing to social isolation, depression, and cognitive decline. These effects highlight the urgent need for effective therapeutic interventions. The underlying mechanisms of hearing loss are complex and multifactorial, involving oxidative stress, inflammation, and cellular damage within the cochlea. Oxidative stress, marked by an overproduction of reactive oxygen species (ROS), plays a crucial role in the development of several types of hearing loss, including noise-induced hearing loss (NIHL), ototoxicity, and age-related hearing loss.[2] ROS can damage cochlear hair cells, spiral ganglion neurons (SGNs), and other vital structures in the inner ear, leading to permanent hearing impairment.[34] Additionally, glutamate excitotoxicity and mitochondrial dysfunction have been linked to hearing loss, particularly in cases of cochlear ischemia and noise trauma.[567] Current treatments for hearing loss include corticosteroids, hyperbaric oxygen therapy, vasodilators, and intratympanic steroid injections, particularly for ISSNHL.[18] However, these treatments often have limited efficacy and may be associated with significant side effects. Therefore, there is a pressing need for novel therapeutic approaches that can target the underlying mechanisms of hearing loss with minimal side effects. Hydrogen therapy has emerged as a promising therapeutic approach, leveraging its potent antioxidant and anti-inflammatory properties. Molecular hydrogen (H2) exhibits a selective scavenging effect on harmful ROS, such as hydroxyl radicals and peroxynitrite, while preserving physiologically relevant ROS signaling pathways.[9] This selective antioxidant action has been demonstrated in diverse disease contexts, including cerebral infarction, myocardial infarction, and type 2 diabetes.[1011] Given its safety profile and efficacy in reducing oxidative stress, hydrogen therapy holds significant potential as a treatment for hearing loss. So far, there have not been any systematic reviews looking into this field. Our review aims to explore the therapeutic effects of hydrogen therapy on hearing loss, focusing on its mechanisms of action and clinical applications. MATERIALS AND METHODS This review is in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline.[12] Study Design A systematic literature search was performed in PubMed, MEDLINE, and DOAJ to identify peer-reviewed articles on the hydrogen therapy for hearing loss. Search terms included variations of “hearing loss” and “hydrogen.” Reference lists of relevant publications were also reviewed. Two independent researchers screened articles based on titles and abstracts using the pre-defined search criteria. The final search was conducted on March 1, 2025. Study Eligibility Included studies should meet the following criteria: (1) human, animal or hair cell subjects; (2) the target disease of the study should be any kind of hearing loss, including noise-induced hearing loss, drug-induced hearing loss (DIHL), and radiotherapy-induced hearing loss or idiopathic; (3) studies focusing on hydrogen treatment efficacy instead of mechanism exploration; (4) the study was an original research report; and (5) articles written in English. Study of mechanism without any assessment of treatment effectiveness, non-English studies, and review articles were excluded from the review. Data Extraction All data were extracted for the following variables: (1) article title, (2) 1st author, (3) year of publication, (4) study subject, (5) type of hydrogen agent, (6) outcome measure, and (7) main findings. Due to significant heterogeneity and inconsistent statistical reporting across studies, meta-analysis and publication bias assessment were not feasible. Data were independently extracted by two authors and subsequently cross-checked. Result Synthesis Data were organized into separate tables based on hearing loss type. Each table presented key study information, including first author, publication year, study subjects, hydrogen agent used, and a concise summary of the main findings. Risk of Bias and Quality Assessment The risk of bias (RoB) and quality assessment for animal studies were conducted using a well-established Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) RoB tool for animal studies.[13] Two authors conducted their evaluation independently using the SYRCLE RoB inventory, after independant evaluation, disagreement was discussed, if not solved, the third author will be consulted. While the cell study and case report study were not evaluated for bias due to lack of golden-standard evaluation tool. Figure Processing The SYRCLE figure presented in results section were processed using GraphPad Prism version 9.5 (GraphPad Software, San Diego, CA, USA). While the flow diagram was processed using Microsoft PowerPoint (Microsoft Corp., Redmond, WA, USA). RESULTS The study selection process was summarized in the flowchart shown in Figure 1. A total of 11 articles were included in this systematic review. The study selection process. Hydrogen Therapy in Noise-Induced Hearing Loss These included studies, conducted primarily in animal models, highlight the efficacy of hydrogen in mitigating the oxidative stress and inflammation that underlie NIHL [Table 1]. Table 1The studies descriptions in noise-induced hearing lossAuthorYearSubjectHydrogen agentOutcome measureMain findingsLin[14]2011Guinea pigHydrogen-rich waterABR, DPOAEsThe ABR thresholds at 2 and 4 kHz were significantly better on post-noise days 1, 3, and 14 in hydrogen-treated animals. The hydrogen-treated animals also showed greater amplitude of DPOAE input/output growth functions during the recovery process.Chen[15]2014Guinea pigHydrogen-saturated salineABR, DPOAEsThe subjects in the hydrogen group had lower level of average ABR threshold shift of 54 dB SPL compared to 62 dB SPL in control group. The guinea pigs in the hydrogen group had less decrease in DPOAE amplitudes at frequencies of 0.5–4 kHz.Fransson[16]2021Guinea pigInhaled hydrogenABRABR thresholds were significantly lower in H2-treated animals at 2 weeks after exposureKurioka[17]2014Guinea pigInhaled hydrogenABRSeven days after noise exposure, the threshold shift of the H2-treated group was less than that of the non-treated group at any frequency.Chen[18]2017Guinea pigHydrogen-saturated salineABRThe guinea pigs in hydrogen-saturated saline group had an average ABR threshold shift of 53 dB SPL, lower than control group of 61 dB SPL.Zhou[19]2012Guinea pigHydrogen-saturated salineABR, DPOAEsThe hydrogen-rich saline group showed a significantly decreased ABR threshold value and the most recovered DPOAEs compared with other groups.Note: ABR, auditory brainstem response; dB, decibel; DPOAEs, distortion product otoacoustic emissions; kHz, kilohertz; SPL, sound pressure level. The studies descriptions in noise-induced hearing loss Note: ABR, auditory brainstem response; dB, decibel; DPOAEs, distortion product otoacoustic emissions; kHz, kilohertz; SPL, sound pressure level. The primary mechanism underlying the protective effects of hydrogen therapy in NIHL is its potent antioxidant activity. Hydrogen selectively scavenges harmful ROS, such as hydroxyl radicals (•OH) and peroxynitrite (ONOO–), which are excessively generated during noise exposure and contribute significantly to cochlear damage.[141516] By effectively reducing ROS levels, hydrogen therapy mitigates oxidative damage to critical cochlear structures, including hair cells, SGNs, and other essential components of the inner ear. Furthermore, hydrogen therapy exhibits significant anti-inflammatory properties. Chen et al.[18] demonstrated that hydrogen-saturated saline effectively reduced the levels of pro-inflammatory cytokines [Interleukin-1 (IL-1), Interleukin-6 (IL-6), Tumor Necrosis Factor-α (TNF-α)] but increased the intercellular adhesion molecules-1 within the cochlea 7 days following noise exposure, while concomitantly increasing the levels of anti-inflammatory cytokines [nterleukin-10 (IL-10)]. This dual-pronged action of hydrogen—effectively mitigating both oxidative stress and inflammation—positions it as a particularly promising therapeutic intervention for NIHL. Moreover, Fransson et al.[16] demonstrated that hydrogen gas inhalation effectively protected cochlear synaptic structures and significantly reduced outer hair cell (OHC) loss, suggesting a potential role for hydrogen in preserving the functional integrity of the cochlea by stabilizing synaptic connections and mitigating apoptotic processes. These findings align with those of Kurioka et al.,[17] who reported that hydrogen gas inhalation led to improved auditory brainstem response (ABR) thresholds and a significant reduction in oxidative DNA damage [8-Hydroxy-2’-deoxyguanosine (8-OHdG)] in noise-exposed guinea pigs. Several studies have shown that hydrogen therapy, whether administered through hydrogen-rich water, hydrogen-saturated saline, or hydrogen gas inhalation, significantly attenuates NIHL. For instance, Lin et al.[14] demonstrated that guinea pigs treated with hydrogen-rich water exhibited better recovery of ABR thresholds and distortion-product otoacoustic emissions after noise exposure compared to controls. Similarly, Chen et al.[15] found that pre-treatment with hydrogen-saturated saline reduced noise-induced hair cell damage and hearing loss, with lower levels of malondialdehyde and hydroxyl radicals, indicating reduced oxidative stress. These findings are further supported by Zhou et al.,[19] which showed that hydrogen-rich saline significantly decreased ABR threshold shifts and im-proved OHC survival after noise exposure. While the preclinical evidence for hydrogen therapy in NIHL is compelling, several challenges remain before it can be widely adopted in clinical practice. First, most of the studies reviewed here were conducted in animal models, and the translation of these findings to humans requires further investigation. Second, the optimal dosing, timing, and duration of hydrogen therapy need to be established. For instance, Kurioka et al.[17] explored different concentrations of hydrogen gas (0.5%, 1.0%, and 1.5%) and found that higher concentrations (1.0% and 1.5%) were more effective in protecting against NIHL. Future studies should aim to determine the most effective and safe dosing regimens for different populations. Finally, the long-term effects of hydrogen therapy on hearing preservation and its potential interactions with other treatments (e.g., corticosteroids) should be explored. Chen et al.[15] and Zhou et al.[19] suggest that hydrogen therapy may have synergistic effects with other anti-inflammatory and antioxidant treatments, which could enhance its therapeutic potential. In conclusion, hydrogen therapy proved to be effective in preclinical studies in NIHL by scavenging ROS and alleviating inflammatory responses, and further clinical translational studies are required for the consolidation of its efficacy. Hydrogen Therapy in Drug-Induced Hearing Loss DIHL is a significant clinical problem, often caused by ototoxic drugs such as aminoglycosides, cisplatin, and loop diuretics. These drugs can lead to irreversible damage to cochlear hair cells and SGNs, resulting in sensorineural hearing loss [Table 2]. Table 2The studies descriptions in drug-induced hearing lossAuthorYearSubjectHydrogen agentOutcome measureMain findingsTaura[20]2010Vestibular hair cellHydrogen gasFM1-43 accumulation, ROS productionThe number of FM1-43-positive hair cells in the groups treated with hydrogen gas was significantly larger when compared with the group treated with antimycin A alone (P < 0.0001). While the HPF-positive hair cells in the group treated with hydrogen gas was significantly smaller (P < 0.0001).Qu[11]2012Mongolian gerbilsInhaled hydrogenABR, DPOAEsTreatment with H2 (2% and 4%) markedly attenuated the click and tone burst-evoked ABR threshold shift at 4, 8, and 16 kHz in ouabain-exposed animals. And can significantly alleviate SGN damage and attenuate the loss of SGN density for each turn of cochlea in ouabain-exposed animals.Note: HPF, hydroxyphenyl fluorescein; SGN, spiral ganglion neurons. The studies descriptions in drug-induced hearing loss Note: HPF, hydroxyphenyl fluorescein; SGN, spiral ganglion neurons. The primary mechanism by which hydrogen therapy exerts its protective effects in DIHL is through its potent antioxidant properties. Hydrogen selectively scavenges ROS, which are generated in excess during ototoxic drug exposure and contribute to cellular damage. Taura et al.[20] demonstrated that hydrogen gas significantly reduced ROS levels in vestibular hair cells exposed to antimycin A, as measured by hydroxyphenyl fluorescein fluorescence. This reduction in ROS levels correlated with preserved hair cell morphology and function, indicating that hydrogen therapy can effectively reduce oxidative stress-induced damage. In addition to its antioxidant effects, hydrogen therapy also exhibits anti-apoptotic properties. As a result, hydrogen gas preserved the morphology and function of hair cells, as evidenced by the increased number of myosin VIIa-positive cells and FM1-43 accumulation, indicating intact mechano-electrical transduction channels.[20] Ouabain, a Na+/K+-ATPase inhibitor, selectively damages SGNs without affecting hair cells. Qu et al.[11] showed that hydrogen gas inhalation reduced caspase-3 activity and TUNEL-positive SGNs in ouabain-exposed gerbils, indicating a reduction in apoptosis. This suggests that hydrogen therapy can protect SGNs from ototoxic drug-induced apoptosis by inhibiting the caspase-dependent apoptotic pathway. Which in turn leads to significantly attenuated the ABR threshold shifts and reduced SGN apoptosis, suggesting that hydrogen therapy can protect against SGN damage induced by ototoxic drugs.[11] While the preclinical evidence for hydrogen therapy in DIHL is promising, several challenges remain before it can be widely adopted in clinical practice. First, most of the studies reviewed here were conducted in animal models, and the translation of these findings to humans requires further investigation. Clinical trials are needed to evaluate the safety and efficacy of hydrogen therapy in patients receiving ototoxic drugs, such as cisplatin or aminoglycosides. In conclusion, hydrogen therapy represents a promising approach for the prevention and treatment of DIHL. Its ability to selectively scavenge harmful ROS, reduce apoptosis, and protect both hair cells and SGNs makes it a unique and effective intervention. Hydrogen Therapy in Radiotherapy-Induced Hearing Loss Radiotherapy-induced hearing loss (RIHL) is a significant complication for patients undergoing radiation therapy, particularly for head and neck cancers such as nasopharyngeal carcinoma (NPC). The auditory system, including the cochlea, auditory nerves, and middle ear structures, is highly sensitive to radiation, leading to progressive hearing impairment. Recent studies have explored the potential of hydrogen therapy as a protective and therapeutic intervention for RIHL. The mechanisms by which hydrogen therapy exerts its protective effects in RIHL are likely similar to those observed in other forms of hearing loss, as proposed by the included studies. Radiation therapy generates excessive ROS in the cochlea and auditory nerves, leading to oxidative stress, inflammation, and cellular damage. Hydrogen therapy selectively scavenges harmful ROS, such as hydroxyl radicals, while preserving physiological ROS involved in cellular signaling. The included studies represent the first attempts to evaluate the efficacy of hydrogen therapy in human subjects with RIHL, particularly those who have undergone radiotherapy for NPC. These studies provide preliminary evidence that hydrogen therapy may be a promising intervention for RIHL. Kong et al.[21] conducted a prospective study to evaluate the clinical efficacy and safety of hydrogen inhalation in improving hearing loss in patients with long-term survival of NPC after radiotherapy [Table 3]. The study included 17 patients who had developed hearing loss following radiotherapy. After 4 weeks of hydrogen inhalation, significant improvements were observed in eustachian tube dysfunction scores, air conduction thresholds, and bone conduction thresholds. Although the improvements in air-bone gap and tympanogram scores were not statistically significant, the study demonstrated a clear trend toward hearing improvement, with no adverse effects reported. This suggests that hydrogen inhalation may be a safe and effective rehabilitation therapy for patients with RIHL. Table 3The studies descriptions in radiotherapy-induced hearing lossAuthorYearSubjectHydrogen agentOutcome measureMain findingsKong[21]2022Nasopharyngeal carcinoma patientsInhaled hydrogenThe eustachian tube dysfunction score, pure tone air conduction threshold, bone conduction threshold, the score of tympanogram and otoscopeAfter 4 weeks of hydrogen inhalation, the score of eustachian tube dysfunction, air conduction, and bone conduction hearing thresholds were significantly reduced, P-values were 0.0293, 0.0027, 0.0404, respectively. While the changes were not significant in the mean air-bone gap, the score of otoscopy and tympanogram.Chen[22]2019Nasopharyngeal carcinoma patientsInhaled hydrogenPure tone air conduction threshold, bone conduction threshold, otoscopeAfter 0.5, 1, and 2 months of continuous hydrogen–oxygen therapy, our first three patients reported different levels of improvement in binaural hearing. The studies descriptions in radiotherapy-induced hearing loss Chen et al.[22] reported on three patients with NPC who developed binaural secretory otitis media after radiotherapy. Despite conventional treatments, their hearing continued to deteriorate until they experienced severe hearing loss. After undergoing hydrogen-oxygen therapy for 0.5–2 months, all three patients reported varying degrees of improvement in binaural hearing. While the preliminary clinical findings on hydrogen therapy for RIHL are promising, several challenges remain before it can be widely adopted in clinical practice. First, the number of clinical studies on hydrogen therapy for RIHL is limited, and larger, well-designed randomized controlled trials are needed to confirm its efficacy and safety. The study by Okada et al.[23] provides a strong foundation and references for designing future trials, but more research is needed to determine the optimal dosing, timing, and duration of hydrogen therapy for RIHL. Second, the long-term effects of hydrogen therapy on hearing preservation and its potential interactions with other treatments (e.g., antioxidants, anti-inflammatory drugs) should be explored. Preclinical studies suggest that hydrogen therapy may have synergistic effects with other treatments that target oxidative stress and inflammation, which could enhance its therapeutic potential. In conclusion, the included clinical studies provide preliminary evidence that hydrogen therapy can improve hearing in patients with RIHL, particularly those who have undergone radiotherapy for NPC. However, further research is needed to confirm these findings, optimize treatment protocols, and explore the long-term benefits of hydrogen therapy. Hydrogen Therapy in Idiopathic Sudden Sensorineural Hearing Loss Okada et al.[24] represent the first and only clinical trial to investigate the efficacy of hydrogen therapy for hearing loss in humans [Table 4]. Although this study focuses only on ISSNHL, its findings are highly relevant to the broader field of hydrogen therapy for hearing loss. The study was a double-blind randomized controlled trial involving 65 patients with ISSNHL, who were randomly assigned to receive either H2 or placebo (air) in combination with systemic glucocorticoids and prostaglandin E1. The primary outcome was the change in hearing threshold 3 months after therapy. Table 4The studies descriptions in ISSNHLAuthorYearSubjectHydrogen agentOutcome measureMain findingsOkada[24]2022ISSNHL patientsInhaled hydrogenHearing thresholdThe changes in hearing threshold 3 months after treatment was 32.7 dB (95% CI: 24.2–41.3) and 24.2 dB (95% CI: 18.1–30.3) in the H2 and control groups, respectively. Consequently, the changes in hearing threshold were significantly better in the H2 group than in the control group (P = 0.048). The studies descriptions in ISSNHL The results showed that the change in hearing threshold was significantly better in the H2 group compared to the control group (32.7 dB vs. 24.2 dB, P = 0.048), suggesting that hydrogen therapy may enhance the recovery of hearing in patients with ISSNHL. Importantly, no adverse effects were reported, highlighting the safety of hydrogen inhalation. Certain novel materials were also developed to deliver hydrogen to the inner ear. Xiao et al. developed a spacestation-like composite nanoparticles (CCC@mPP NPs) with pH/oxidation dual responsiveness, it can carry multiple medication along with ammonia borane as the hydrogen-generating agent. Though the drug-loaded material demonstrated good anti-inflammatory effect in the inner ear, the combination therapy did not highlight the efficacy of hydrogen monotherapy.[25] Risk of Bias Assessment for Animal Studies Based on the SYRCLE RoB tool assessment of the seven included studies, the overall methodological quality and reporting of the included seven animal experiments are concerning, indicating a high risk of bias across multiple domains. Critical methodological safeguards against bias, such as allocation concealment (Q3) and blinding of caregivers and investigators (Q5), were not implemented in five studies. While random outcome assessment (Q6) was confirmed in three studies and assessor blinding (Q7) in two, these practices were not consistently reported or applied. The absence of selective outcome reporting (Q9) in five studies is a strength. However, the lack of information on sequence generation (Q1), baseline group similarity (Q2), random housing (Q4), and handling of incomplete outcome data (Q8)—all rated as “unclear” for every study—severely limits the ability to assess selection, performance, and attrition bias. This systematic review highlights a significant need for improved methodological rigor and transparent reporting in future animal studies on this topic to enhance the reliability and translatability of their findings [Figure 2]. The SYRCLE’s risk of bias evaluation of animal experiments. DISCUSSION Hearing loss, whether induced by noise, ototoxic drugs, radiotherapy, or idiopathic causes, represents a significant global health challenge with profound impacts on quality of life.[12627] The studies reviewed indicate that hydrogen therapy may offer a novel and effective treatment for various types of hearing loss, primarily by alleviating oxidative stress and inflammation—key contributors to auditory damage. By selectively scavenging harmful ROS, including hydroxyl radicals, hydrogen therapy has shown protective effects in preclinical models of NIHL, DIHL, and RIHL. This potential is further supported by emerging clinical evidence, particularly in the context of RIHL and ISSNHL, where hydrogen therapy has improved hearing outcomes with few side effects. The mechanisms behind hydrogen therapy’s effectiveness are complex. It reduces oxidative stress, modulates inflammatory pathways, and prevents apoptosis in cochlear hair cells and SGNs.[11] For example, in NIHL, hydrogen therapy helps preserve cochlear synapses and reduces OHC loss.[16] In DIHL, it protects SGNs from apoptosis induced by ototoxic drugs.[11] Similarly, in RIHL, hydrogen therapy alleviates radiation-induced damage, improving hearing thresholds, and reducing oxidative stress markers in clinical studies.[21] Despite these promising results, several challenges remain. Much of the current evidence comes from preclinical studies and small-scale clinical trials, highlighting the need for larger, well-designed randomized controlled trials to confirm the safety and efficacy of hydrogen therapy in humans. The extrapolation of animal data on hydrogen therapy for hearing loss to human applications faces significant limitations. Species-specific differences in cochlear biology, antioxidant defense systems, and immune responses may alter treatment efficacy across organisms.[28] Pharmacokinetic variations, including differences in hydrogen absorption, distribution, and metabolism between rodents and humans, further complicate dosage translation.[29] Additionally, the optimal dosing, timing, and duration of treatment must be determined, especially for different patient groups and types of hearing loss. Future research should also investigate the long-term effects of hydrogen therapy, its potential synergistic effects with other treatments (e.g., corticosteroids, antioxidants), and its detailed mechanisms of action. In terms of risk of bias, the identified methodological limitations, particularly in allocation concealment and blinding, significantly undermine the validity of the included studies’ findings. The lack of detail regarding randomization sequences, baseline comparability, and handling of attrition data further exacerbates concerns over selection, performance, and attrition biases. Future animal studies must adopt more rigorous design and reporting practices. Standardized reporting guidelines like Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies or Animal Research: Reporting of In Vivo Experiments guidelines should be strictly followed to enhance transparency.[3031] Ultimately, these improvements are crucial for enhancing the reliability and translatability of preclinical evidence. This systematic review also has several limitations that must be acknowledged. First, the significant heterogeneity among the included studies (heterogeneity in study subjects) precluded a quantitative synthesis of the results via meta-analysis. The studies varied considerably in their experimental designs, including the animal models used (e.g., guinea pigs, gerbils, mice), the methods of hydrogen administration (inhalation, saturated saline injection, rich water), the protocols for inducing hearing loss (noise parameters, ototoxic drug dosage), and the timing of outcome assessments. This clinical and methodological diversity makes it statistically inappropriate and misleading to pool the results. Second, the exclusion of non-English publications may have introduced a language bias, potentially overlooking relevant data published in other languages. This exclusion risks skewing the evidence base, as studies with positive or negative findings from non-English speaking regions may be absent, which can affect the overall comprehensiveness and generalizability of the review’s conclusions. Future systematic reviews on this topic would benefit from broader language inclusion criteria to minimize this potential bias and ensure a more representative synthesis of the global evidence. Although conventional delivery methods, such as hydrogen-rich saline or inhaled hydrogen, offer convenience and cost-effectiveness, their ability to transport hydrogen efficiently is limited. This results in suboptimal bioavailability in body fluids and target tissues. Furthermore, the therapeutic effects of these methods are often short-lived, as hydrogen is rapidly eliminated from the body following inhalation or ingestion/injection of hydrogen-enriched solutions. To address these limitations, researchers have developed innovative hydrogen-producing agents, including water/acid-reactive compounds and catalytic materials. These novel medications have demonstrated promising therapeutic efficacy in preclinical studies, offering a more sustainable and effective alternative to traditional delivery systems.[32] For instance, hydrogen carriers have gained attention as a strategy offering more targeted delivery and higher loading capacity than traditional approaches. Palladium (Pd)-based carriers, for example, upon hydrogen absorption, Pd is converted into palladium hydride (PdH), which promotes sustained localized release of bio-reductive hydrogen.[33] Beyond hydrogen carriers, several novel hydrogen-generating agents have been developed and have demonstrated promising therapeutic outcomes in preclinical research. For example, silicon-based nano-powders react with water to produce substantial amounts of hydrogen under physiological conditions (e.g., 400 mL from 1 g at pH 8.3 and 36°C)—equivalent to the hydrogen content in 22 L of saturated hydrogen-rich water—confirming their high hydrogen-generation efficiency.[34] Further advances include catalytic systems that enhance hydrogen production from specific reactions, particularly through externally triggered photocatalysts and sonocatalysts. A noticeable photocatalyst is the multicomponent biomimetic assembly designed by Wan et al., inspired by natural photosynthesis. This system incorporates a photosensitizer (chlorophyll a, Chla), an electron donor (L-ascorbic acid, AA), and a catalyst (gold nanoparticles, AuNPs) co-encapsulated in liposomes (Lip). Under 660 nm laser irradiation, Chla becomes excited (Chla), generating electron–hole pairs. The holes in Chla accept electrons from AA, returning it to its ground state, while AuNPs catalyze the reduction of protons (from AA) using electrons from Chla to form hydrogen gas.[35] On the other hand, the first reported sonocatalyst consisted of Pt-Bi2S3 metal–semiconductor heterostructure nanocomposites, which can produce hydrogen in deep tissues where light penetration is limited. Besides systemic administration, these carriers, reactants, and catalysts can also be given through tympanic injection or even round window injection for more precise delivery to the inner ear. CONCLUSION In conclusion, hydrogen therapy offers a promising and innovative approach to preventing and treating hearing loss in preclinical setting. By targeting the oxidative and inflammatory processes underlying auditory damage, it provides a safe and effective intervention. However, further research is essential to fully assess its therapeutic potential and integrate it into clinical practice, as well as exploring more efficient novel hydrogen-producing materials in hearing loss treatment. Availability of Data and Materials No new data generated. Author Contributions Conceptualization, Wang CZ and Ainiwaer M.; methodology, Zheng J.; writing—original draft preparation, CZ Wang and M Ainiwaer; writing—review and editing, CZ Wang, M Ainiwaer, J Zheng, and LH Wang; visualization, CZ Wang and M Ainiwaer; supervision, J Zheng and LH Wang; project administration, J Zheng and LH Wang. All authors have read and agreed to the published version of the manuscript. Ethics Approval and Consent to Participate Not applicable. Conflicts of Interest The authors declare no conflicts of interest.